Noticias

Flux RSS
 
18/07/2016
bioMérieux – Second-Quarter 2016 Business Review

Más
22/04/2016
BIOMERIEUX CELEBRA EL II SIMPOSIO NACIONAL DE VETERINARIA

Más
20/04/2016
bioMérieux – First-Quarter 2016 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2016.
Más
02/03/2016
bioMérieux – 2015 Financial Results

Más
26-01-2016
El panel de Meningitis/Encefalitis FilmArray® de BioFire obtiene el marcaje CE
El portfolio ampliado de FilmArray®, con un cuarto panel, es el mayor disponible en una plataforma multiplex de biología molecular.
Más
21-01-26
Fourth-Quarter 2015 Business Review

Más
12/01/16
BioFire Presenta la Petición Especial 510(k) a la FDA para el uso de FilmArray® Torch, el Nuevo sistema FilmArray® de Alto Rendimiento con el Panel Respiratorio FilmArray®
FilmArray® Torch ofrece alto rendimiento, en un espacio radicalmente más pequeño
Más
22-10-2015
bioMérieux – Business review for the nine months ended September 30, 2015

Más
31-08-2015
bioMérieux - First-Half 2015 Results

  Strong growth in business

  • €933 million in sales
  • Up 19.5% as reported
  • Up 8.1% like-for-like
  • Sharp 34% improvement in contributive operating income before non-recurring items lifted by strong business momentum, the disciplined management of operating expenses and the positive currency effect
 Sustained successful performance by FilmArray®
 510(k) FDA clearance of VIDAS® 3
 Execution of the industrial investment plan
 Confirmation of the 2015 financial objectives

 


Más
11-03-2015
bioMérieux - 2014 Financial Results

 Solid growth in sales:

  • Up 8.7%, including BioFire and at constant exchange rates
  • Up 3.8%, at constant exchange rates and scope of consolidation
Contributive operating income before non-recurring items*: €227 million, in line with the objective set at the beginning of the year
Sustained successful sales performance by BioFire and FilmArray® in molecular biology
Significant strategic and operating advances, with the signature of eight business development agreements
Higher contributive operating income before non-recurring items* expected in 2015, while the Company continues its efforts in sales & marketing, production and innovation, as well as its priority action plans to sustainably strengthen operating performance.

Más